183 related articles for article (PubMed ID: 19345914)
1. Effects of pioglitazone on menstrual frequency, hyperandrogenism and insulin resistance in adoloscents and young adults with polycystic ovary syndrome.
Narsing Rao L; Jacob JJ; Paul TV; Rajarathinam S; Thomas N; Seshadri MS
J Pediatr Adolesc Gynecol; 2009 Apr; 22(2):91-5. PubMed ID: 19345914
[TBL] [Abstract][Full Text] [Related]
2. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
Ortega-González C; Cardoza L; Coutiño B; Hidalgo R; Arteaga-Troncoso G; Parra A
J Endocrinol; 2005 Jan; 184(1):233-9. PubMed ID: 15642799
[TBL] [Abstract][Full Text] [Related]
3. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
Yilmaz M; Karakoç A; Törüner FB; Cakir N; Tiras B; Ayvaz G; Arslan M
Gynecol Endocrinol; 2005 Sep; 21(3):154-60. PubMed ID: 16335907
[TBL] [Abstract][Full Text] [Related]
4. Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome.
Stabile G; Borrielli I; Artenisio AC; Bruno LM; Benvenga S; Giunta L; La Marca A; Volpe A; Pizzo A
J Pediatr Adolesc Gynecol; 2014 Jun; 27(3):177-82. PubMed ID: 24814528
[TBL] [Abstract][Full Text] [Related]
5. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome.
Cho LW; Kilpatrick ES; Keevil BG; Coady AM; Atkin SL
Clin Endocrinol (Oxf); 2009 Feb; 70(2):233-7. PubMed ID: 18547343
[TBL] [Abstract][Full Text] [Related]
6. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Ortega-González C; Luna S; Hernández L; Crespo G; Aguayo P; Arteaga-Troncoso G; Parra A
J Clin Endocrinol Metab; 2005 Mar; 90(3):1360-5. PubMed ID: 15598674
[TBL] [Abstract][Full Text] [Related]
7. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
8. Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome.
Garmes HM; Tambascia MA; Zantut-Wittmann DE
Gynecol Endocrinol; 2005 Dec; 21(6):317-23. PubMed ID: 16390779
[TBL] [Abstract][Full Text] [Related]
9. Does metformin induce ovulation in normoandrogenic anovulatory women?
Carmina E; Lobo RA
Am J Obstet Gynecol; 2004 Nov; 191(5):1580-4. PubMed ID: 15547527
[TBL] [Abstract][Full Text] [Related]
10. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
[TBL] [Abstract][Full Text] [Related]
11. Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome.
Cataldo NA; Abbasi F; McLaughlin TL; Basina M; Fechner PY; Giudice LC; Reaven GM
Hum Reprod; 2006 Jan; 21(1):109-20. PubMed ID: 16155076
[TBL] [Abstract][Full Text] [Related]
12. [Clinical, hormonal and biochemical changes after treatment with metformin and weight reduction in women with polycystic ovary syndrome].
Pekhlivanov B; Mitkov M; Kavŭrdzhikova S
Akush Ginekol (Sofiia); 2006; 45(6):29-35. PubMed ID: 17168480
[TBL] [Abstract][Full Text] [Related]
13. Pioglitazone reduces central obesity in polycystic ovary syndrome women.
Asadipooya K; Kalantar-Hormozi M; Nabipour I
Gynecol Endocrinol; 2012 Jan; 28(1):16-9. PubMed ID: 21756079
[TBL] [Abstract][Full Text] [Related]
14. Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment.
Højlund K; Glintborg D; Andersen NR; Birk JB; Treebak JT; Frøsig C; Beck-Nielsen H; Wojtaszewski JF
Diabetes; 2008 Feb; 57(2):357-66. PubMed ID: 17977950
[TBL] [Abstract][Full Text] [Related]
15. Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study.
Penna IA; Canella PR; Reis RM; Silva de Sá MF; Ferriani RA
Hum Reprod; 2005 Sep; 20(9):2396-401. PubMed ID: 16006454
[TBL] [Abstract][Full Text] [Related]
16. Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study.
Naka KK; Kalantaridou SN; Kravariti M; Bechlioulis A; Kazakos N; Calis KA; Makrigiannakis A; Katsouras CS; Chrousos GP; Tsatsoulis A; Michalis LK
Fertil Steril; 2011 Jan; 95(1):203-9. PubMed ID: 20684955
[TBL] [Abstract][Full Text] [Related]
17. Treatment options of polycystic ovary syndrome in adolescence.
Zapanti E; Kiapekou E; Loutradis D
Pediatr Endocrinol Rev; 2006 Jan; 3 Suppl 1():208-13. PubMed ID: 16641862
[TBL] [Abstract][Full Text] [Related]
18. [Use of yasmin in the treatment of women with polycystic ovary syndrome].
Pekhlivanov B; Mitkov M; Ivancheva Kh; Amaliev I
Akush Ginekol (Sofiia); 2006; 45(3):25-9. PubMed ID: 16889184
[TBL] [Abstract][Full Text] [Related]
19. Metformin treatment is effective in obese teenage girls with PCOS.
De Leo V; Musacchio MC; Morgante G; Piomboni P; Petraglia F
Hum Reprod; 2006 Sep; 21(9):2252-6. PubMed ID: 16785260
[TBL] [Abstract][Full Text] [Related]
20. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome.
Brettenthaler N; De Geyter C; Huber PR; Keller U
J Clin Endocrinol Metab; 2004 Aug; 89(8):3835-40. PubMed ID: 15292314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
